Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020

Udgivet den 29-04-2020  |  kl. 13:15  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the Company), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day.  The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 8473556, approximately 15 minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com.  The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company.  We bring energy and invention to a world in need of diagnostic truth.  Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease.  The T-SPOT.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company is headquartered near Oxford, U.K. and in Marlborough, MA.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Novo præsenterer data ved konference for blodsygdomme i USA
Novo/Sydbank: Ikke den store overraskelse at Zepbound giver større vægttab end Wegovy
Vestas får amerikansk ordre på 342 MW
Vestas får kursklø efter finansdirektørs exit
Tryg varsler milliardudbytter og et forsikringsresultat på over 8 mia. kr. i 2027
 

Seneste nyheder

06:32 Asien: Politisk kaos i Sydkorea lægger dæmper på aktiemarkederne
06:32 Valuta: Sydkoreanske won stabiliseret efter politisk kaos
06:32 USA/T-bond: Rentekurven stejlede tirsdag
06:30 Kalender med link - onsdag den 4. december
17:49 Europa/lukning: Teknologi og energi bag fjerde dag på stribe i grønt
17:06 Tirsdagens obligationer: Flad renteudvikling efter otte dag i streg med fald
17:04 Tirsdagens aktier: GN og NKT blev presset mest i rødt C25
16:38 MT Højgaard opjusterer efter salg af grund i Høje Taastrup
16:08 GN presses efter negativ analyse fra Bank of America
16:03 USA præget af flere ledige stillinger på jobmarkedet i oktober
16:02 Chemometec opjusterer forventningerne
15:40 USA/åbning: Små fald fra rekordterritorium med fokus på nøgletal
14:56 Tørlastindekset Baltic Dry falder med 4,7 pct.
14:38 USA/tendens: Rekorderne ligger lige på vippen med fokus på nøgletal
14:33 Novo præsenterer data ved konference for blodsygdomme i USA
13:48 Europa/middag: Energi og teknologi driver Stoxx 600 mod fjerde dag i grønt
12:39 Carlsberg bør kunne føre penge for Baltika ud af Rusland
12:14 Tivoli med kurs mod rekordresultat: Vi står stærkere over hele vores forretning
11:42 Carlsberg bekræfter salg af Baltika Breweries: Handlen ventes afsluttet om få dage
11:36 Carlsberg bekræfter salg af Baltika Breweries: Handlen ventes afsluttet om få dage